Artificial Intelligence within Clinical Systems

What to Expect

Timely, Interactive Format.

We are all aware the industry has changed over the last few years. The evolution seems to be continuing. What should we be expecting in the near and long term future for clinical trial operation, and how will DCT components come into play? Is there a cost/benefit profile that fits within DCT? Is it more or less expensive and what are the efficiencies that come into play if it is more expensive? A discussion on these pieces has been ongoing and we need to continue toward a resolution.

Online Agenda

Ask 20 people and you may get 30 different definitions of DCT. What exactly do people mean when they say they want a decentralized trial?

Is it a significant player in future trials, or just a passing fad? What are its implications for Oncology trials? We have seen pieces such as big data and social media claim to be the answer to patient recruitment, but it has not come to fruition.

Is it less or more expensive to integrate DCT into a protocol? The answer can be either and has many factors coming into play.

Why you should attend

We invite you to contribute your expertise to an exclusive virtual boardroom discussion about DCT. The virtual boardroom is limited to 25 participants only. Each participant shall have the opportunity to raise questions and vividly contribute to the discussion.

Meet the Facilitator

The virtual boardroom will be lead by our expert Facilitator

Jeffrey Zucker

Senior Vice President, DCT Solutions & Trial Operations Worldwide Clinical Trials

<p><span style="font-weight: 400;">Mr. Zucker’s current responsibilities include growing and continually improving WCT’s Decentralized Clinical Trials (DCT) offerings, oversight of Feasibility and Recruitment Optimization, Cognitive Assessment Technologies (CAT), and RBQM offerings at WCT. He has been in the clinical research industry for over 25 years, most of which has been focused on Clinical Operations, Rater Training, Feasibility, Patient Recruitment, and Site Identification & Relations. Prior to WCT, Mr. Zucker was a psychotherapist working on conducting and training clinicians on various rating scales.  He also worked with various large pharmaceutical companies, other CROs, started his own consulting company working with sites and pharmaceutical companies, and started up and directed research sites (including a Phase I unit). Mr. Zucker holds a Psychology Degree (B.S.) from Pennsylvania State University, a Masters in Group Process and Group Psychotherapy (M.S.) from Hahnemann University, and a Certificate in International Business Management from the University College of Dublin in Ireland.</span></p>

More about Worldwide Clinical Trials:

More information

Worldwide Clinical Trials is a global, mid-sized, Contract Research Organization (CRO) that provides top-performing, preclinical, and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries. Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post approval, and real-world evidence. Major therapeutic areas of focus include Cardiovascular, Metabolic, Neuroscience, Oncology, and Rare Diseases. With infrastructure spanning 60 countries and offices in North and South America, Eastern and Western Europe, Russia and Asia, Worldwide is powered by its more than 2,600 employee experts. We are the cure for the common CRO. For more information, please visit https://www.worldwide.com/.

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials Worldwide Clinical Trials

Worldwide Clinical Trials Virtual Boardroom 3rd May 2022

Worldwide Clinical Trials Virtual Boardroom

DCT is officially here… now what?

Virtual Boardroom

Timely, Interactive Format.

Online Agenda

What is DCT?

Shelf life of DCT:

Value proposition for DCT:

Why you should attend

Meet the Facilitator

Jeffrey Zucker

More about Worldwide Clinical Trials:

Further Information

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

100-500

500+

This is required field*

This is required field*

Under £100,000

£100,000 - £500,000

£500,000 - £1,000,000

£1,000,000 - £5,000,000

£5,000,000 - £10,000,000

£10,000,000 +

This is required field*

This is required field*

Discovery to Development

Pre-Clinical

Phase 1

Phase 2

Phase 3

Phase 4